Navigation Links
Grant for brain tumor and deafness research
Date:7/27/2009

Researchers at the Peninsula Medical School have received a grant of over 39,000 from the charity Deafness Research UK, to investigate the role of brain tumours causing deafness in children and adults and the development of therapies using in vitro models.

These tumours and a variety of other tumours are caused by mutations affecting a protein called merlin, which in turn cause cancers in a range of cell types including Schwann cells in the nervous system. Schwann cells produce the sheaths that surround and insulate neurons.

Although the tumours are benign, they are frequent. They can be inherited and come in numbers. The sheer number of them can overwhelm a patient, often leading to deafness and eventually to death. Patients can suffer from 20 to 30 tumours at any one time, and the condition typically affects older children and young adults.

No therapy, other than invasive surgery aiming at a single tumour and which may not eradicate the full extent of the tumours, exists. The hereditary condition affects one in every 2,500 people worldwide. It can affect any family, regardless of past history, through gene mutation and currently there is no cure.

In some cases, pressure from the tumours affect the process of hearing leading to hearing loss or total deafness. The research will use a human acoustic neuroma in vitro model to identify how and why the tumours grow and eventually lead to hearing damage, and to test drug-based therapies designed to alleviate the problem.

The research is led by Professor Oliver Hanemann, Chair of Clinical Neurobiology at the Peninsula Medical School. He said: "We have already achieved some success in re-profiling an existing drug called sorafenib by using the human in-cell model. The re-profiled drug has a positive affect on multiple brain tumours. As a consequence, we can go straight to clinical trials and introduce therapies to patients sooner rather than later using sorafenib or similar drugs.."

Vivienne Michael, Chief Executive of Deafness Research UK, said: "This is clearly an important research project that could significantly improve the treatment available for those with acoustic neuroma and the charity is delighted to be funding it. Acoustic neuroma is worrying enough in its own right; when multiple tumours occur they need treating and traditional cancer therapies are not an option. Currently, treatment involves surgical removal of the tumours but this leads to damage of the auditory nerve and can cause total deafness with potentially devastating effects on the lives of those involved.

"Great progress has been made in identifying target molecules for treatment, and this research will go a long way towards establishing the best potential drug for non-invasive therapy. Ultimately this would avoid the need for surgery and mean that people who currently face deafness as a result of acoustic neuroma would retain their hearing."


'/>"/>

Contact: Andrew Gould
andrew.gould@pms.ac.uk
The Peninsula College of Medicine and Dentistry
Source:Eurekalert

Related medicine news :

1. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
2. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
3. $21.8 Million NIH Grant for Fragile X Research
4. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
5. Boston University School of Medicine researcher recipient of Memory Ride Grant
6. RAND researchers offer options to improve immigrant health care quality, access
7. Pennsylvania Department of Aging Receives Grant to Improve Alzheimers Support
8. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
9. NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity
10. Johns Hopkins receives $100 million grant to speed research from clinic to community
11. Major grant advances UWs clinical and translational research enterprise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... , ... August 18, 2017 ... ... Quick International, LLC (“Quick”), a highly specialized asset-light logistics provider of complex ... into a definitive agreement to purchase Unitrans International Corporation, a division of ...
(Date:8/18/2017)... ... 18, 2017 , ... As an industry leader, Eppendorf is ... will present the line of epMotion automated liquid handling system. This automated liquid ... everyday pipetting tasks. , Ideal for scientists and lab technicians with no or ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston ... east Texas, is launching a regional charity effort to provide publicity assistance and ... Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... The Golseth ... in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to provide ... , In early June of this year, Christina and her children returned from out ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., a ... , today announced that the company has provided an ... of North Carolina at Chapel Hill and to Qura ... to characterize and quantify HIV reservoir and viral expression ... intervention. The HIV Cure Center is a joint initiative ...
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
(Date:8/7/2017)... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ...  All comparisons, unless otherwise noted, are to the quarter ended ... Second Quarter 2017 Highlights include: Revenue ... 3.5% Total prescriptions dispensed of 220,000, compared ... 7.6% Gross profit per prescription dispensed ...
Breaking Medicine Technology: